Marc Foca

Marc Foca

Auto-generated profile, based on publicly available information

Marc Foca

Montefiore Medical Center, Bronx, NY

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2017 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Open access
PDF file
SRSarah M Ramteke
Sarah M Ramteke
SSStephanie Shiau
Stephanie Shiau
MFMarc Foca
Marc Foca
RSRenate Strehlau
Renate Strehlau
FPFrancoise Pinillos
Francoise Pinillos
SAStephen M Arpadi
Stephen M Arpadi
Prior research in sub-Saharan Africa reports dyslipidemia in perinatally human immunodeficiency virus (HIV)-infected children receiving ritonavir-boosted lopinavir (LPV/r) compared with efavirenz; however, interpretation of findings is limited by lack of comparison data from HIV-uninfected children. We conducted a cross-sectional analysis of lipid profiles and growth within a larger longitudinal cohort study of perinatally HIV-infected and HIV-uninfected children aged 4–9 years in Johannesburg, South Africa. At enrollment, anthropometrics, viral load, CD4, total cholesterol (TC), high-density lipoprotein, low-density lipoprotein (LDL), and triglycerides were measured. Weight-for-age Z-score (WAZ), height-for-age Z-score (HAZ), and body mass index-for-age Z-score (BAZ) were calculated. United States pediatric thresholds for dyslipidemia were used. Five hundred fifty-three HIV-infected and 300 HIV-uninfected children (median age 6.9 years) of similar demographic characteristics were enrolled. Of the HIV-infected children, 94.8% were on combination antiretroviral therapy (cART) (65.4% on LPV/r- and 28.6% on efavirenz-based regimens). Among the treated, 94.3% had a viral load <200 copies/mL. Median CD4% was 34.4. The HIV-infected children had lower mean WAZ (−0.7 vs −0.3, P < .01) and HAZ (−1.1 vs −0.7, P < .01) compared with HIV-uninfected children. A lower proportion of HIV-infected children were overweight (BAZ >1) compared with HIV-uninfected children (14.4% vs 21.7%, P = .04). Whether on LPV/r or efavirenz, a higher proportion of HIV-infected children had borderline/elevated TC or abnormal triglycerides than HIV-uninfected children, although a higher proportion of those on LPV/r had borderline/elevated TC, borderline/elevated LDL, or abnormal triglycerides than those on efavirenz. In a South African cohort of HIV-infected children and population-appropriate HIV-uninfected children, unfavorable alterations in lipid profiles were detected in HIV-infected children regardless of treatment regimen compared with HIV-uninfected children. The HIV-infected children were of smaller size than HIV-uninfected children, but there was a high prevalence of overweight in both groups. Strategies for optimizing growth and early life management of lipid alterations may be warranted.

1 July 2006 in Pediatrics
Verified
Journal Article
Closed access
PDF file
MFMarc Foca
Marc Foca
JMJack Moye
Jack Moye
CCClara Chu
Clara Chu
YMYvonne Matthews
Yvonne Matthews
KRKen Rich
Ken Rich
WSWomen and Infants Transmission Study
Women and Infants Transmission Study
OBJECTIVE. We sought to document gender differences in lymphocyte subsets and plasma RNA levels in a pediatric cohort with presumed minimal hormonal differences (on the basis of age). METHODS. Blood samples from antiretroviral therapy-treated, HIV-infected children (n = 158) and HIV-uninfected children (n = 1801) who were enrolled in the Women and Infants Transmission Study were analyzed at specified study intervals with consensus protocols, and various parameters were compared. RESULTS. Antiretroviral therapy-treated, HIV-infected female children had, on average, 0.38 log10 copies per mL lower plasma RNA levels than did their male counterparts, but lymphocyte differences were not noted in this cohort. Despite their higher plasma RNA level, a greater proportion of male children survived through 8 years of age. There were no gender differences with respect to the age of diagnosis of HIV, time to antiretroviral therapy after diagnosis of HIV, or type of antiretroviral therapy. Lymphocyte differences were noted for uninfected children. CONCLUSIONS. Plasma RNA levels differed among antiretroviral therapy-treated, HIV-infected children according to gender, in a manner similar to that noted in previous pediatric and adult studies. Lymphocyte subsets varied according to gender in a cohort of HIV-exposed but uninfected children. Most importantly, overall mortality rates for this cohort differed according to gender.

26 July 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
SDSalih Demirhan
Salih Demirhan
FMFlor M. Munoz
Flor M. Munoz
KDKristen G. Valencia Deray
Kristen G. Valencia Deray
CBClaire E. Bocchini
Claire E. Bocchini
LDLara Danziger-Isakov
Lara Danziger-Isakov
BHBetsy C. Herold
Betsy C. Herold
Optimal dosing of valganciclovir (VGCV) for cytomegalovirus (CMV) prevention in pediatric solid organ transplantation recipients (SOTR) is controversial. Dosing calculated based on body surface area and creatinine clearance (BSA) is recommended but simplified body weight (BW) dosing is often prescribed. We conducted a retrospective six center study to compare safety and efficacy of these strategies in the first-year post-transplantation. There were 100 (24.2%) pediatric SOTR treated with BSA and 312 (75.7%) with BW dosing. CMV DNAemia was documented in 31.0% versus 23.4% (p=0.1) at any time during the first year and breakthrough DNAemia in 16% versus 12.2% (p=0.3) of pediatric SOTR receiving BSA versus BW dosing, respectively. However, neutropenia (50% versus 29.3%, p<0.001), lymphopenia (51% versus 15.0%, p<0.001) and acute kidney injury causing treatment modification (8.0% versus 1.8%, p<0.001) were documented more frequently during prophylaxis in pediatric SOTR receiving BSA versus BW dosing. The adjusted odds ratio of VGCV attributed toxicities comparing BSA and BW dosing was 2.3 [95% CI, 1.4-3.7] for neutropenia, 7.0 [95% CI, 3.9-12.4] for lymphopenia, and 4.6 [95% CI, 2.2-9.3] for premature discontinuation or dose reduction of VGCV, respectively. Results demonstrate that BW dosing is associated with significantly less toxicity without any increase in CMV DNAemia.

28 June 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
MFMarc Foca
Marc Foca
SDSalih Demirhan
Salih Demirhan
FMFlor M Munoz
Flor M Munoz
KDKristen G Valencia Deray
Kristen G Valencia Deray
CBClaire E Bocchini
Claire E Bocchini
BHBetsy C. Herold
Betsy C. Herold
Valganciclovir is the only approved antiviral for cytomegalovirus (CMV) prevention in pediatric solid organ transplantation (SOT). Additional approaches may be needed to improve outcomes. A multicenter retrospective study from 2016 to 2019 was conducted of pediatric SOT recipients in whom at least 3 months of valganciclovir prophylaxis was planned. Episodes of CMV DNA in blood (DNAemia), CMV disease, drug-related toxicities, as well as other infections in the first year posttransplant and demographic and clinical data were collected. CMV DNAemia in the first year after prophylaxis or during prophylaxis (breakthrough) was analyzed by multivariate hazard models. Among the 749 patients enrolled, 131 (17.5%) had CMV DNAemia at any time in the first year; 85 (11.4%) had breakthrough DNAemia, and 46 (6.1%) had DNAemia after prophylaxis. CMV disease occurred in 30 (4%). In a multivariate model, liver transplantation compared to kidney or heart, intermediate or high risk based on donor/recipient serologies, neutropenia, and valganciclovir dose modifications attributed to toxicity were associated with increased risk of total and/or breakthrough DNAemia. Bacteremia was also associated with increased hazard ratio for CMV DNAemia. In a separate multivariate analysis, rejection occurred more often in those with breakthrough CMV DNAemia (P = .002); liver transplants, specifically, had increased rejection if CMV DNAemia occurred in the first year (P = .004). These associations may be bidirectional as rejection may contribute to infection risk. CMV DNAemia in the first year posttransplantation occurs despite valganciclovir prophylaxis and is associated with medication toxicity, bacteremia, and rejection. Pediatric studies of newer antivirals, especially in higher-risk subpopulations, appear to be warranted.

22 June 2026 in Hepatology
Verified
Journal Article
Closed access
MMMercedes Martinez
Mercedes Martinez
AAAdebowale Adeyemi
Adebowale Adeyemi
JCJaime Chu
Jaime Chu
ACAndrew Costandi
Andrew Costandi
MFMarc D. Foca
Marc D. Foca
VNVicky Lee Ng
Vicky Lee Ng
Background and Aims: Liver transplantation is a lifesaving, standard of care intervention for infants, children, and adolescents with liver tumors, inborn errors of metabolism, and irreversible liver disease caused by a wide spectrum of liver conditions. The American Association for the Study of Liver Diseases (AASLD) last published guidelines for the evaluation and selection of pediatric liver transplant candidates in 2014. This 2026 update aims to provide evidence-based recommendations that reflect current best practices and evolving clinical knowledge. Methods: A multidisciplinary writing group of pediatric liver transplant experts and a medical librarian was convened by AASLD, with guidance by its Practice Guidelines Development Policy, and in collaboration with the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) and the American Society of Transplantation (AST). We conducted a systematic global literature review, formulated key clinical questions, and developed recommendations. Each recommendation was graded using the Oxford Centre for Evidence-Based Medicine framework and categorized by strength through a consensus voting process. Conclusion: This document provides clear, evidence-based guidelines on the transplant evaluation process and journey in infants, children, and adolescents. It outlines indications, contraindications, and barriers to transplantation based on robust, relevant published data. It offers best practices for pre-transplant assessment, organ allocation, and strategies to optimize survival, while allowing flexibility for individual clinical scenarios.